We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Adverum Biotechnologies Inc (ADVM) USD0.0001

Sell:$7.68 Buy:$8.17 Change: $0.04 (0.51%)
Market closed |  Prices as at close on 22 May 2024 | Switch to live prices |
Change: $0.04 (0.51%)
Market closed |  Prices as at close on 22 May 2024 | Switch to live prices |
Change: $0.04 (0.51%)
Market closed |  Prices as at close on 22 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Contact details

100 Cardinal Way
United States
+1 (650) 6491004

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$171.24 million
Shares in issue:
20.76 million
United States
US dollar

Key personnel

  • Laurent Fischer
    President, Chief Executive Officer, Director
  • Linda Rubinstein
    Chief Financial Officer
  • Kishor Soparkar
    Chief Operating Officer
  • Andrew Ramelmeier
    Chief Technology Officer
  • Romuald Corbau
    Chief Scientific Officer
  • Brigit Riley
    Chief Scientific Officer
  • John Rakow
    General Counsel
  • Setareh Seyedkazemi
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.